{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:02:21Z","timestamp":1792890141927,"version":"4.5.0"},"reference-count":195,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41571-024-00965-0","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T13:19:00Z","timestamp":1731935940000},"page":"28-45","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-6288","authenticated-orcid":false,"given":"Paolo","family":"Cirac\u00ec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Studiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2153-3867","authenticated-orcid":false,"given":"Ada","family":"Taravella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Antoniotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-4841","authenticated-orcid":false,"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"965_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"965_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer 103, 356\u2013387 (2018).","journal-title":"Eur. J. Cancer"},{"key":"965_CR3","doi-asserted-by":"publisher","first-page":"S1271","DOI":"10.1016\/j.annonc.2023.10.024","volume":"34","author":"K-K Shiu","year":"2023","unstructured":"Shiu, K.-K. et al. LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)\/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study. Ann. Oncol. 34, S1271\u2013S1272 (2023).","journal-title":"Ann. Oncol."},{"key":"965_CR4","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe, J. et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA 329, 1271\u20131282 (2023).","journal-title":"JAMA"},{"key":"965_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"C Cremolini","year":"2020","unstructured":"Cremolini, C. et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 21, 497\u2013507 (2020).","journal-title":"Lancet Oncol."},{"key":"965_CR6","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1200\/JCO.22.01693","volume":"41","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem, E. et al. ANCHOR CRC: results from a single-arm, phase II study of encorafenib plus binimetinib and cetuximab in previously untreated BRAFV600E-mutant metastatic colorectal cancer. J. Clin. Oncol. 41, 2628\u20132637 (2023).","journal-title":"J. Clin. Oncol."},{"key":"965_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1200\/JOP.2010.000072","volume":"6","author":"GP Hess","year":"2010","unstructured":"Hess, G. P., Wang, P. F., Quach, D., Barber, B. & Zhao, Z. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J. Oncol. Pract. 6, 301\u2013307 (2010).","journal-title":"J. Oncol. Pract."},{"key":"965_CR8","doi-asserted-by":"publisher","first-page":"e748","DOI":"10.3747\/co.26.4861","volume":"26","author":"H Kennecke","year":"2019","unstructured":"Kennecke, H. et al. A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada. Curr. Oncol. 26, e748\u2013e754 (2019).","journal-title":"Curr. Oncol."},{"key":"965_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.clcc.2015.10.003","volume":"15","author":"J McLean","year":"2016","unstructured":"McLean, J. et al. Clinical practice patterns in chemotherapeutic treatment regimens for metastatic colorectal cancer. Clin. Colorectal Cancer 15, 135\u2013140 (2016).","journal-title":"Clin. Colorectal Cancer"},{"key":"965_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejca.2022.04.019","volume":"170","author":"D Rossini","year":"2022","unstructured":"Rossini, D. et al. Treatments after second progression in metastatic colorectal cancer: a pooled analysis of the TRIBE and TRIBE2 studies. Eur. J. Cancer 170, 64\u201372 (2022).","journal-title":"Eur. J. Cancer"},{"key":"965_CR11","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1200\/JCO.2015.61.2887","volume":"33","author":"DP Modest","year":"2015","unstructured":"Modest, D. P. et al. Impact of subsequent therapies on outcome of the FIRE-3\/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. J. Clin. Oncol. 33, 3718\u20133726 (2015).","journal-title":"J. Clin. Oncol."},{"key":"965_CR12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/annonc\/mdw627","volume":"28","author":"F Pietrantonio","year":"2017","unstructured":"Pietrantonio, F. et al. Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Ann. Oncol. 28, 555\u2013561 (2017).","journal-title":"Ann. Oncol."},{"key":"965_CR13","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem, E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386\u20131422 (2016).","journal-title":"Ann. Oncol."},{"key":"965_CR14","doi-asserted-by":"publisher","first-page":"101558","DOI":"10.1016\/j.esmoop.2023.101558","volume":"8","author":"T Yoshino","year":"2023","unstructured":"Yoshino, T. et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. ESMO Open 8, 101558 (2023).","journal-title":"ESMO Open"},{"key":"965_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337\u2013345 (2004).","journal-title":"N. Engl. J. Med."},{"key":"965_CR16","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris, V. K. et al. Treatment of metastatic colorectal cancer: ASCO guideline. J. Clin. Oncol. 41, 678\u2013700 (2023).","journal-title":"J. Clin. Oncol."},{"key":"965_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes, A. et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 10\u201332 (2023).","journal-title":"Ann. Oncol."},{"key":"965_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.annonc.2023.10.129","volume":"35","author":"A Cervantes","year":"2024","unstructured":"Cervantes, A. & Martinelli, E. Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO metastatic colorectal cancer living guideline. Ann. Oncol. 35, 241\u2013243 (2024).","journal-title":"Ann. Oncol."},{"key":"965_CR19","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/02841860510029662","volume":"44","author":"M Gubanski","year":"2005","unstructured":"Gubanski, M., Naucler, G., Almerud, A., Lidest\u00e5hl, A. & Lind, P. A. R. M. Capecitabine as third line therapy in patients with advanced colorectal cancer. Acta Oncol. 44, 236\u2013239 (2005).","journal-title":"Acta Oncol."},{"key":"965_CR20","first-page":"2971","volume":"31","author":"MW Saif","year":"2011","unstructured":"Saif, M. W. et al. The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience. Anticancer. Res. 31, 2971\u20132974 (2011).","journal-title":"Anticancer. Res."},{"key":"965_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.clinre.2013.11.006","volume":"38","author":"Y Liu","year":"2014","unstructured":"Liu, Y. et al. Raltitrexed-based chemotherapy for advanced colorectal cancer. Clin. Res. Hepatol. Gastroenterol. 38, 219\u2013225 (2014).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"965_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1177\/030089160609200404","volume":"92","author":"L Rimassa","year":"2006","unstructured":"Rimassa, L. et al. Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin. Tumori 92, 285\u2013289 (2006).","journal-title":"Tumori"},{"key":"965_CR23","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ejca.2012.01.008","volume":"48","author":"R Ferrarotto","year":"2012","unstructured":"Ferrarotto, R. et al. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur. J. Cancer 48, 820\u2013826 (2012).","journal-title":"Eur. J. Cancer"},{"key":"965_CR24","doi-asserted-by":"publisher","first-page":"102112","DOI":"10.1016\/j.ctrv.2020.102112","volume":"91","author":"G Mauri","year":"2020","unstructured":"Mauri, G. et al. Oxaliplatin retreatment in metastatic colorectal cancer: systematic review and future research opportunities. Cancer Treat. Rev. 91, 102112 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"965_CR25","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.2147\/DDDT.S85567","volume":"9","author":"M Suenaga","year":"2015","unstructured":"Suenaga, M. et al. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des. Devel. Ther. 9, 3099\u20133108 (2015).","journal-title":"Drug Des. Devel. Ther."},{"key":"965_CR26","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3390\/cancers14051197","volume":"14","author":"A Amatu","year":"2022","unstructured":"Amatu, A. et al. Efficacy of retreatment with oxaliplatin-based regimens in metastatic colorectal cancer patients: the RETROX-CRC retrospective study. Cancers 14, 1197 (2022).","journal-title":"Cancers"},{"key":"965_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303\u2013312 (2013).","journal-title":"Lancet"},{"key":"965_CR28","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","volume":"16","author":"J Li","year":"2015","unstructured":"Li, J. et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 16, 619\u2013629 (2015).","journal-title":"Lancet Oncol."},{"key":"965_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1634\/theoncologist.2018-0072","volume":"24","author":"E Van Cutsem","year":"2019","unstructured":"Van Cutsem, E. et al. Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single-arm, open-label phase IIIb CONSIGN study. Oncologist 24, 185\u2013192 (2019).","journal-title":"Oncologist"},{"key":"965_CR30","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/j.jfma.2020.12.015","volume":"120","author":"K-H Yeh","year":"2021","unstructured":"Yeh, K.-H. et al. Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan. J. Formos. Med. Assoc. 120, 2023\u20132031 (2021).","journal-title":"J. Formos. Med. Assoc."},{"key":"965_CR31","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1200\/JCO.2018.36.4_suppl.748","volume":"36","author":"H Schulz","year":"2018","unstructured":"Schulz, H. et al. Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: final results of the prospective multicentre non-interventional RECORA study. J. Clin. Oncol. 36, 748 (2018).","journal-title":"J. Clin. Oncol."},{"key":"965_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4137\/CMO.S38335","volume":"10","author":"F Calcagno","year":"2016","unstructured":"Calcagno, F. et al. Efficacy, safety and cost of regorafenib in patients with metastatic colorectal cancer in french clinical practice. Clin. Med. Insights Oncol. 10, 59\u201366 (2016).","journal-title":"Clin. Med. Insights Oncol."},{"key":"965_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2440-9","volume":"16","author":"A Adenis","year":"2016","unstructured":"Adenis, A. et al. Survival, safety, and prognostic factors for outcome with regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer 16, 412 (2016).","journal-title":"BMC Cancer"},{"key":"965_CR34","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1200\/jco.2013.31.15_suppl.3637","volume":"31","author":"A Grothey","year":"2013","unstructured":"Grothey, A. et al. Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. J. Clin. Oncol. 31, 3637 (2013).","journal-title":"J. Clin. Oncol."},{"key":"965_CR35","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","volume":"20","author":"TS Bekaii-Saab","year":"2019","unstructured":"Bekaii-Saab, T. S. et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 20, 1070\u20131082 (2019).","journal-title":"Lancet Oncol."},{"key":"965_CR36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejca.2022.09.037","volume":"177","author":"G Argil\u00e9s","year":"2022","unstructured":"Argil\u00e9s, G. et al. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). Eur. J. Cancer 177, 154\u2013163 (2022).","journal-title":"Eur. J. Cancer"},{"key":"965_CR37","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909\u20131919 (2015).","journal-title":"N. Engl. J. Med."},{"key":"965_CR38","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","volume":"13","author":"T Yoshino","year":"2012","unstructured":"Yoshino, T. et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 13, 993\u20131001 (2012).","journal-title":"Lancet Oncol."},{"key":"965_CR39","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","volume":"36","author":"J Xu","year":"2018","unstructured":"Xu, J. et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J. Clin. Oncol. 36, 350\u2013358 (2018).","journal-title":"J. Clin. Oncol."},{"key":"965_CR40","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ctrv.2015.06.001","volume":"41","author":"H-J Lenz","year":"2015","unstructured":"Lenz, H.-J., Stintzing, S. & Loupakis, F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat. Rev. 41, 777\u2013783 (2015).","journal-title":"Cancer Treat. Rev."},{"key":"965_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000752","volume":"5","author":"J Tabernero","year":"2020","unstructured":"Tabernero, J. et al. Effect of trifluridine\/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis. ESMO Open 5, e000752 (2020).","journal-title":"ESMO Open"},{"key":"965_CR42","doi-asserted-by":"publisher","first-page":"100391","DOI":"10.1016\/j.esmoop.2022.100391","volume":"7","author":"L Weiss","year":"2022","unstructured":"Weiss, L. et al. Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine\/tipiracil: results of the TALLISUR trial. ESMO Open 7, 100391 (2022).","journal-title":"ESMO Open"},{"key":"965_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000698","volume":"5","author":"J-B Bachet","year":"2020","unstructured":"Bachet, J.-B. et al. Safety, efficacy and patient-reported outcomes with trifluridine\/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. ESMO Open 5, e000698 (2020).","journal-title":"ESMO Open"},{"key":"965_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10489-4","volume":"23","author":"J Taieb","year":"2023","unstructured":"Taieb, J. et al. Safety and efficacy of trifluridine\/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy. BMC Cancer 23, 94 (2023).","journal-title":"BMC Cancer"},{"key":"965_CR45","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.2018.7855","volume":"319","author":"J Li","year":"2018","unstructured":"Li, J. et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA 319, 2486 (2018).","journal-title":"JAMA"},{"key":"965_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari, A. et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 402, 41\u201353 (2023).","journal-title":"Lancet"},{"key":"965_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1200\/JCO.2023.41.4_suppl.67","volume":"41","author":"AF Sobrero","year":"2023","unstructured":"Sobrero, A. F. et al. Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study. J. Clin. Oncol. 41, 67 (2023).","journal-title":"J. Clin. Oncol."},{"key":"965_CR48","unstructured":"US Food and Drugs Administration. FDA D.I.S.C.O. Burst Edition: FDA approval of Fruzaqla (fruquintinib) for adult patients with metastatic colorectal cancer. fda.gov https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-fruzaqla-fruquintinib-adult-patients-metastatic-colorectal#:~:Text=On%20November%208%2C%202023%2C%20the,%2C%20an%20anti%2DEGFR%20therapy (2023)."},{"key":"965_CR49","unstructured":"European Medicines Agency. Fruzaqla. ema.europa.eu https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fruzaqla (2024)."},{"key":"965_CR50","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1200\/JCO.2024.42.16_suppl.3536","volume":"42","author":"J Peng","year":"2024","unstructured":"Peng, J. et al. Efficacy and safety of fruquintinib plus trifluridine\/tipiracil (TAS-102) as third-line treatment in patients with metastatic colorectal adenocarcinoma: Results from a single arm, phase 2, multicenter study. J. Clin. Oncol. 42, 3536 (2024).","journal-title":"J. Clin. Oncol."},{"key":"965_CR51","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager, G. W. et al. Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer. N. Engl. J. Med. 388, 1657\u20131667 (2023).","journal-title":"N. Engl. J. Med."},{"key":"965_CR52","unstructured":"US Food and Drugs Administration. FDA approves trifluridine and tipiracil with bevacizumab for previously treated metastatic colorectal cancer. fda.gov https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-trifluridine-and-tipiracil-bevacizumab-previously-treated-metastatic-colorectal-cancer (2023)."},{"key":"965_CR53","unstructured":"European Medicines Agency. Lonsurf. Trifluridine\/tipiracil. ema.europa.eu https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-lonsurf-ii-26_en.pdf? (2023)."},{"key":"965_CR54","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.annonc.2021.03.206","volume":"32","author":"A Grothey","year":"2021","unstructured":"Grothey, A., Fakih, M. & Tabernero, J. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Ann. Oncol. 32, 959\u2013967 (2021).","journal-title":"Ann. Oncol."},{"key":"965_CR55","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.20.02088","volume":"39","author":"J Tabernero","year":"2021","unstructured":"Tabernero, J. et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J. Clin. Oncol. 39, 273\u2013284 (2021).","journal-title":"J. Clin. Oncol."},{"key":"965_CR56","doi-asserted-by":"publisher","first-page":"100506","DOI":"10.1016\/j.esmoop.2022.100506","volume":"7","author":"A Boccaccino","year":"2022","unstructured":"Boccaccino, A. et al. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ESMO Open 7, 100506 (2022).","journal-title":"ESMO Open"},{"key":"965_CR57","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41416-024-02711-w","volume":"131","author":"K Zwart","year":"2024","unstructured":"Zwart, K. et al. Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab. Br. J. Cancer 131, 110\u2013116 (2024).","journal-title":"Br. J. Cancer"},{"key":"965_CR58","doi-asserted-by":"publisher","first-page":"S446","DOI":"10.1016\/j.annonc.2023.09.1816","volume":"34","author":"C Gallois","year":"2023","unstructured":"Gallois, C. et al. 625P Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: an AGEO real-world multicentre study. Ann. Oncol. 34, S446 (2023).","journal-title":"Ann. Oncol."},{"key":"965_CR59","doi-asserted-by":"publisher","first-page":"102996","DOI":"10.1016\/j.esmoop.2024.102996","volume":"9","author":"MM Germani","year":"2024","unstructured":"Germani, M. M. et al. Treatment of patients with BRAF-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset. ESMO Open 9, 102996 (2024).","journal-title":"ESMO Open"},{"key":"965_CR60","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1200\/JCO.2023.41.4_suppl.126","volume":"41","author":"A Fernandez Montes","year":"2023","unstructured":"Fernandez Montes, A. et al. Effectiveness and safety of encorafenib-cetuximab in BRAF V600E metastatic colorectal cancer: confidence study. J. Clin. Oncol. 41, 126\u2013126 (2023).","journal-title":"J. Clin. Oncol."},{"key":"965_CR61","doi-asserted-by":"publisher","first-page":"114290","DOI":"10.1016\/j.ejca.2024.114290","volume":"210","author":"M Ambrosini","year":"2024","unstructured":"Ambrosini, M. et al. BRAF + EGFR +\/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer. Eur. J. Cancer 210, 114290 (2024).","journal-title":"Eur. J. Cancer"},{"key":"965_CR62","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.annonc.2023.02.016","volume":"34","author":"J Ros","year":"2023","unstructured":"Ros, J. et al. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann. Oncol. 34, 543\u2013552 (2023).","journal-title":"Ann. Oncol."},{"key":"965_CR63","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1038\/s41591-022-01976-z","volume":"28","author":"E Elez","year":"2022","unstructured":"Elez, E. et al. RNF43 mutations predict response to anti-BRAF\/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. Nat. Med. 28, 2162\u20132170 (2022).","journal-title":"Nat. Med."},{"key":"965_CR64","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1093\/oncolo\/oyac265","volume":"28","author":"JCF Quintanilha","year":"2023","unstructured":"Quintanilha, J. C. F., Graf, R. P. & Oxnard, G. R. BRAF V600E and RNF43 co-mutations predict patient outcomes with targeted therapies in real-world cases of colorectal cancer. Oncologist 28, e171\u2013e174 (2023).","journal-title":"Oncologist"},{"key":"965_CR65","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00255","volume":"7","author":"R Moretto","year":"2023","unstructured":"Moretto, R. et al. Predictive impact of RNF43 mutations in patients with proficient mismatch repair\/microsatellite stable BRAFV600E-mutated metastatic colorectal cancer treated with target therapy or chemotherapy. JCO Precis. Oncol. 7, e2300255 (2023).","journal-title":"JCO Precis. Oncol."},{"key":"965_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03235-9","author":"S Kopetz","year":"2024","unstructured":"Kopetz, S. et al. Molecular profiling of BRAFV600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03235-9 (2024).","journal-title":"Nat. Med."},{"key":"965_CR67","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.annonc.2023.10.120","volume":"35","author":"J Ros","year":"2024","unstructured":"Ros, J., Vivancos, A., Tabernero, J. & \u00c9lez, E. Circulating tumor DNA, and clinical features to guide rechallenge with BRAF inhibitors in BRAF-V600E mutated metastatic colorectal cancer. Ann. Oncol. 35, 240\u2013241 (2024).","journal-title":"Ann. Oncol."},{"key":"965_CR68","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2217\/fon-2022-1249","volume":"20","author":"E Elez","year":"2024","unstructured":"Elez, E. et al. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H\/dMMR BRAFV600E-mutant mCRC. Future Oncol. 20, 653\u2013663 (2024).","journal-title":"Future Oncol."},{"key":"965_CR69","doi-asserted-by":"publisher","first-page":"TPS3619","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3619","volume":"39","author":"S Kopetz","year":"2021","unstructured":"Kopetz, S. et al. BREAKWATER: randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) \u00b1 chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC). J. Clin. Oncol. 39, TPS3619 (2021).","journal-title":"J. Clin. Oncol."},{"key":"965_CR70","doi-asserted-by":"publisher","first-page":"TPS3627","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS3627","volume":"41","author":"S Kopetz","year":"2023","unstructured":"Kopetz, S. et al. BREAKWATER: an open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) \u00b1 chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC). J. Clin. Oncol. 41, TPS3627 (2023).","journal-title":"J. Clin. Oncol."},{"key":"965_CR71","doi-asserted-by":"publisher","first-page":"S1392","DOI":"10.1016\/j.annonc.2022.08.022","volume":"33","author":"J Tabernero","year":"2022","unstructured":"Tabernero, J. et al. LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC). Ann. Oncol. 33, S1392\u2013S1393 (2022).","journal-title":"Ann. Oncol."},{"key":"965_CR72","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","volume":"25","author":"E Missiaglia","year":"2014","unstructured":"Missiaglia, E. et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann. Oncol. 25, 1995\u20132001 (2014).","journal-title":"Ann. Oncol."},{"key":"965_CR73","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.clcc.2018.05.006","volume":"17","author":"K Sawada","year":"2018","unstructured":"Sawada, K. et al. Prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 17, 198\u2013205 (2018).","journal-title":"Clin. Colorectal Cancer"},{"key":"965_CR74","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1200\/JCO.19.01254","volume":"37","author":"F Morano","year":"2019","unstructured":"Morano, F. et al. Negative hyperselection of patients with RAS and BRAF Wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy. J. Clin. Oncol. 37, 3099\u20133110 (2019).","journal-title":"J. Clin. Oncol."},{"key":"965_CR75","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","volume":"1","author":"A Bertotti","year":"2011","unstructured":"Bertotti, A. et al. A molecularly annotated platform of patient-derived xenografts (\u2018xenopatients\u2019) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1, 508\u2013523 (2011).","journal-title":"Cancer Discov."},{"key":"965_CR76","doi-asserted-by":"publisher","first-page":"99ra86","DOI":"10.1126\/scitranslmed.3002442","volume":"3","author":"K Yonesaka","year":"2011","unstructured":"Yonesaka, K. et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 3, 99ra86 (2011).","journal-title":"Sci. Transl. Med."},{"key":"965_CR77","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","volume":"17","author":"A Sartore-Bianchi","year":"2016","unstructured":"Sartore-Bianchi, A. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 17, 738\u2013746 (2016).","journal-title":"Lancet Oncol."},{"key":"965_CR78","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/JCO.2023.41.4_suppl.140","volume":"41","author":"KPS Raghav","year":"2023","unstructured":"Raghav, K. P. S. et al. A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced\/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613. J. Clin. Oncol. 41, 140 (2023).","journal-title":"J. Clin. Oncol."},{"key":"965_CR79","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/oncolo\/oyad200","volume":"28","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab, T. S. et al. Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer: a systematic literature review and meta-analysis of clinical outcomes. Oncologist 28, 885\u2013893 (2023).","journal-title":"Oncologist"},{"key":"965_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38032-4","volume":"14","author":"T Yoshino","year":"2023","unstructured":"Yoshino, T. et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat. Commun. 14, 3332 (2023).","journal-title":"Nat. Commun."},{"key":"965_CR81","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/modpathol.2015.98","volume":"28","author":"E Valtorta","year":"2015","unstructured":"Valtorta, E. et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod. Pathol. 28, 1481\u20131491 (2015).","journal-title":"Mod. Pathol."},{"key":"965_CR82","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2024.42.16_suppl.3509","volume":"42","author":"JH Strickler","year":"2024","unstructured":"Strickler, J. H. et al. Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER). J. Clin. Oncol. 42, 3509 (2024).","journal-title":"J. Clin. Oncol."},{"key":"965_CR83","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer. fda.gov https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer (2023)."},{"key":"965_CR84","volume":"14","author":"S Siena","year":"2021","unstructured":"Siena, S. et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat. Commun. 14, 3332 (2021).","journal-title":"Nat. Commun."},{"key":"965_CR85","doi-asserted-by":"publisher","first-page":"TPS3620","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3620","volume":"39","author":"KPS Raghav","year":"2021","unstructured":"Raghav, K. P. S. et al. Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): a randomized, multicenter, phase 2 study (DESTINY-CRC02). J. Clin. Oncol. 39, TPS3620 (2021).","journal-title":"J. Clin. Oncol."},{"key":"965_CR86","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","volume":"25","author":"K Raghav","year":"2024","unstructured":"Raghav, K. et al. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.Lancet Oncol. 25, 1147\u20131162 (2024).","journal-title":"Lancet Oncol."},{"key":"965_CR87","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-pantumor02 phase II trial. J. Clin. Oncol. 42, 47\u201358 (2024).","journal-title":"J. Clin. Oncol."},{"key":"965_CR88","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to fam-trastuzumab deruxtecan-Nxki for unresectable or metastatic HER2-positive solid tumors. fda.gov https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2 (2024)."},{"key":"965_CR89","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines. Colon Cancer. nccn.org https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1428 (2024)."},{"key":"965_CR90","doi-asserted-by":"publisher","first-page":"TPS261","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS261","volume":"41","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab, T. S. et al. MOUNTAINEER-03: phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer \u2014 trial in progress. J. Clin. Oncol. 41, TPS261 (2023).","journal-title":"J. Clin. Oncol."},{"key":"965_CR91","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior, I. A., Hood, F. E. & Hartley, J. L. The frequency of ras mutations in cancer. Cancer Res. 80, 2969\u20132974 (2020).","journal-title":"Cancer Res."},{"key":"965_CR92","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.prp.2009.07.010","volume":"205","author":"J Neumann","year":"2009","unstructured":"Neumann, J., Zeindl-Eberhart, E., Kirchner, T. & Jung, A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol. Res. Pract. 205, 858\u2013862 (2009).","journal-title":"Pathol. Res. Pract."},{"key":"965_CR93","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","volume":"23","author":"MG Fakih","year":"2022","unstructured":"Fakih, M. G. et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 23, 115\u2013124 (2022).","journal-title":"Lancet Oncol."},{"key":"965_CR94","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41591-023-02717-6","volume":"30","author":"Y Kuboki","year":"2024","unstructured":"Kuboki, Y. et al. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat. Med. 30, 265\u2013270 (2024).","journal-title":"Nat. Med."},{"key":"965_CR95","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih, M. G. et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 389, 2125\u20132139 (2023).","journal-title":"N. Engl. J. Med."},{"key":"965_CR96","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger, R. et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 388, 44\u201354 (2023).","journal-title":"N. Engl. J. Med."},{"key":"965_CR97","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.clcc.2020.04.009","volume":"19","author":"M Schirripa","year":"2020","unstructured":"Schirripa, M. et al. KRAS G12C metastatic colorectal cancer: specific features of a new emerging target population. Clin. Colorectal Cancer 19, 219\u2013225 (2020).","journal-title":"Clin. Colorectal Cancer"},{"key":"965_CR98","first-page":"PO.20.00256","volume":"5","author":"JT Henry","year":"2021","unstructured":"Henry, J. T. et al. Comprehensive clinical and molecular characterization of KRAS G12C-mutant colorectal cancer.JCO Precis. Oncol. 5, PO.20.00256 (2021).","journal-title":"JCO Precis. Oncol."},{"key":"965_CR99","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/oncolo\/oyac077","volume":"27","author":"M Fakih","year":"2022","unstructured":"Fakih, M. et al. Real-world study of characteristics and treatment outcomes among patients with KRAS p.G12C-mutated or other KRAS mutated metastatic colorectal cancer. Oncologist 27, 663\u2013674 (2022).","journal-title":"Oncologist"},{"key":"965_CR100","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2303810","volume":"389","author":"A Sacher","year":"2023","unstructured":"Sacher, A. et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N. Engl. J. Med. 389, 710\u2013721 (2023).","journal-title":"N. Engl. J. Med."},{"key":"965_CR101","doi-asserted-by":"publisher","first-page":"110993","DOI":"10.1016\/j.celrep.2022.110993","volume":"39","author":"MB Ryan","year":"2022","unstructured":"Ryan, M. B. et al. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep. 39, 110993 (2022).","journal-title":"Cell Rep."},{"key":"965_CR102","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio, V. et al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov. 10, 1129\u20131139 (2020).","journal-title":"Cancer Discov."},{"key":"965_CR103","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41591-023-02696-8","volume":"30","author":"J Desai","year":"2024","unstructured":"Desai, J. et al. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat. Med. 30, 271\u2013278 (2024).","journal-title":"Nat. Med."},{"key":"965_CR104","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer. fda.gov https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer (2024)."},{"key":"965_CR105","doi-asserted-by":"publisher","first-page":"LBA3510","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA3510","volume":"42","author":"M Fakih","year":"2024","unstructured":"Fakih, M. et al. Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator\u2019s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC). J. Clin. Oncol. 42, LBA3510 (2024).","journal-title":"J. Clin. Oncol."},{"key":"965_CR106","unstructured":"US National Library of Medicine. ClinicalTrials.org https:\/\/clinicaltrials.gov\/study\/NCT06252649 (2024)."},{"key":"965_CR107","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1016\/j.annonc.2021.05.126","volume":"32","author":"J Tabernero","year":"2021","unstructured":"Tabernero, J. et al. P-71 KRYSTAL-10: a randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation. Ann. Oncol. 32, S121 (2021).","journal-title":"Ann. Oncol."},{"key":"965_CR108","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1002\/cam4.4561","volume":"11","author":"H Wang","year":"2022","unstructured":"Wang, H. et al. NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. Cancer Med. 11, 2541\u20132549 (2022).","journal-title":"Cancer Med."},{"key":"965_CR109","doi-asserted-by":"publisher","unstructured":"Pietrantonio, F. et al. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer. J. Natl Cancer Inst. 109, https:\/\/doi.org\/10.1093\/jnci\/djx089 (2017).","DOI":"10.1093\/jnci\/djx089"},{"key":"965_CR110","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 21, 531\u2013540 (2020).","journal-title":"Lancet Oncol."},{"key":"965_CR111","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1200\/jco.2015.33.15_suppl.2596","volume":"33","author":"MR Patel","year":"2015","unstructured":"Patel, M. R. et al. STARTRK-1: phase 1\/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J. Clin. Oncol. 33, 2596 (2015).","journal-title":"J. Clin. Oncol."},{"key":"965_CR112","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1200\/jco.2015.33.15_suppl.2517","volume":"33","author":"FG De Braud","year":"2015","unstructured":"De Braud, F. G. et al. Alka-372-001: first-in-human, phase I study of entrectinib \u2014 an oral pan-trk, ROS1, and ALK inhibitor \u2014 in patients with advanced solid tumors with relevant molecular alterations. J. Clin. Oncol. 33, 2517 (2015).","journal-title":"J. Clin. Oncol."},{"key":"965_CR113","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1200\/JCO.2022.40.16_suppl.3099","volume":"40","author":"MJ Krzakowski","year":"2022","unstructured":"Krzakowski, M. J. et al. Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced\/metastatic NTRK fusion-positive (NTRK-fp) solid tumors. J. Clin. Oncol. 40, 3099 (2022).","journal-title":"J. Clin. Oncol."},{"key":"965_CR114","unstructured":"US Food and Drug Administration. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC. fda.gov https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc (2019)."},{"key":"965_CR115","unstructured":"US Food and Drug Administration. FDA approves larotrectinib for solid tumors with NTRK gene fusions. fda.gov https:\/\/www.fda.gov\/drugs\/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions (2018)."},{"key":"965_CR116","unstructured":"European Medicines Agency. Rozlytrek. Entrectinib. ema.europa.eu https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rozlytrek (2024)."},{"key":"965_CR117","unstructured":"European Medicines Agency. Vitrakvi. Larotrectinib. ema.europa.eu https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vitrakvi (2019)."},{"key":"965_CR118","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele, R. C. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 21, 271\u2013282 (2020).","journal-title":"Lancet Oncol."},{"key":"965_CR119","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors. fda.gov https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-repotrectinib-adult-and-pediatric-patients-ntrk-gene-fusion-positive (2024)."},{"key":"965_CR120","doi-asserted-by":"publisher","first-page":"S787","DOI":"10.1016\/j.annonc.2023.09.2405","volume":"34","author":"BJ Solomon","year":"2023","unstructured":"Solomon, B. J. et al. 1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial. Ann. Oncol. 34, S787\u2013S788 (2023).","journal-title":"Ann. Oncol."},{"key":"965_CR121","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41698-024-00598-7","volume":"8","author":"Z-J Li","year":"2024","unstructured":"Li, Z.-J. et al. Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis. NPJ Precis. Onc. 8, 100 (2024).","journal-title":"NPJ Precis. Onc."},{"key":"965_CR122","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","volume":"15","author":"A Drilon","year":"2018","unstructured":"Drilon, A., Hu, Z. I., Lai, G. G. Y. & Tan, D. S. W. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat. Rev. Clin. Oncol. 15, 151\u2013167 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"965_CR123","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/annonc\/mdy090","volume":"29","author":"F Pietrantonio","year":"2018","unstructured":"Pietrantonio, F. et al. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann. Oncol. 29, 1394\u20131401 (2018).","journal-title":"Ann. Oncol."},{"key":"965_CR124","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to selpercatinib for pediatric patients two years and older with RET-altered metastatic thyroid cancer or solid tumors. fda.gov https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-selpercatinib-pediatric-patients-two-years-and-older-ret-altered (2024)."},{"key":"965_CR125","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","volume":"23","author":"V Subbiah","year":"2022","unstructured":"Subbiah, V. et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol. 23, 1261\u20131273 (2022).","journal-title":"Lancet Oncol."},{"key":"965_CR126","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S2468-1253(16)30014-0","volume":"1","author":"E Domingo","year":"2016","unstructured":"Domingo, E. et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet Gastroenterol. Hepatol. 1, 207\u2013216 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"965_CR127","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1158\/2159-8290.CD-21-0521","volume":"12","author":"B Rousseau","year":"2022","unstructured":"Rousseau, B. et al. PD-1 blockade in solid tumors with defects in polymerase epsilon. Cancer Discov. 12, 1435\u20131448 (2022).","journal-title":"Cancer Discov."},{"key":"965_CR128","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1093\/hmg\/ddt131","volume":"22","author":"DN Church","year":"2013","unstructured":"Church, D. N. et al. DNA polymerase \u03b5 and \u03b4 exonuclease domain mutations in endometrial cancer. Hum. Mol. Genet. 22, 2820\u20132828 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"965_CR129","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"TCGA Network.","year":"2012","unstructured":"TCGA Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330\u2013337 (2012).","journal-title":"Nature"},{"key":"965_CR130","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.annonc.2024.03.009","volume":"35","author":"M Ambrosini","year":"2024","unstructured":"Ambrosini, M. et al. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Ann. Oncol. 35, 643\u2013655 (2024).","journal-title":"Ann. Oncol."},{"key":"965_CR131","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000147","volume":"8","author":"DM Merino","year":"2020","unstructured":"Merino, D. M. et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J. Immunother. Cancer 8, e000147 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"965_CR132","unstructured":"US Food and Drug Administration. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. fda.gov https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors (2020)."},{"key":"965_CR133","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353\u20131365 (2020).","journal-title":"Lancet Oncol."},{"key":"965_CR134","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1200\/JCO.23.00702","volume":"41","author":"HL Duvivier","year":"2023","unstructured":"Duvivier, H. L. et al. Pembrolizumab in patients with tumors with high tumor mutational burden: results from the targeted agent and profiling utilization registry study. J. Clin. Oncol. 41, 5140\u20135150 (2023).","journal-title":"J. Clin. Oncol."},{"key":"965_CR135","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker, D. J. et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357, 2040\u20132048 (2007).","journal-title":"N. Engl. J. Med."},{"key":"965_CR136","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Van Cutsem","year":"2007","unstructured":"Van Cutsem, E. et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25, 1658\u20131664 (2007).","journal-title":"J. Clin. Oncol."},{"key":"965_CR137","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","volume":"66","author":"A Li\u00e8vre","year":"2006","unstructured":"Li\u00e8vre, A. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992\u20133995 (2006).","journal-title":"Cancer Res."},{"key":"965_CR138","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","volume":"11","author":"W De Roock","year":"2010","unstructured":"De Roock, W. et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11, 753\u2013762 (2010).","journal-title":"Lancet Oncol."},{"key":"965_CR139","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2023.02.006","volume":"184","author":"D Rossini","year":"2023","unstructured":"Rossini, D. et al. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials. Eur. J. Cancer 184, 106\u2013116 (2023).","journal-title":"Eur. J. Cancer"},{"key":"965_CR140","doi-asserted-by":"publisher","first-page":"113975","DOI":"10.1016\/j.ejca.2024.113975","volume":"202","author":"T Yoshino","year":"2024","unstructured":"Yoshino, T. et al. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. Eur. J. Cancer 202, 113975 (2024).","journal-title":"Eur. J. Cancer"},{"key":"965_CR141","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1093\/annonc\/mdx546","volume":"28","author":"C Cremolini","year":"2017","unstructured":"Cremolini, C. et al. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. Ann. Oncol. 28, 3009\u20133014 (2017).","journal-title":"Ann. Oncol."},{"key":"965_CR142","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00037","volume":"6","author":"G Randon","year":"2022","unstructured":"Randon, G. et al. Negative ultraselection of patients with RAS\/BRAF wild-type, microsatellite-stable metastatic colorectal cancer receiving anti-EGFR-based therapy. JCO Precis. Oncol. 6, e2200037 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"965_CR143","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer. Nat. Med. 30, 730\u2013739 (2024).","journal-title":"Nat. Med."},{"key":"965_CR144","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1200\/JCO.22.01922","volume":"41","author":"RB Corcoran","year":"2023","unstructured":"Corcoran, R. B. Line by line: distinct patterns of anti-EGFR antibody resistance by line of therapy. J. Clin. Oncol. 41, 436\u2013438 (2023).","journal-title":"J. Clin. Oncol."},{"key":"965_CR145","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532\u2013536 (2012).","journal-title":"Nature"},{"key":"965_CR146","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1158\/1078-0432.CCR-14-2821","volume":"21","author":"S Arena","year":"2015","unstructured":"Arena, S. et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin. Cancer Res. 21, 2157\u20132166 (2015).","journal-title":"Clin. Cancer Res."},{"key":"965_CR147","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature11219","volume":"486","author":"LA Diaz","year":"2012","unstructured":"Diaz, L. A. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537\u2013540 (2012).","journal-title":"Nature"},{"key":"965_CR148","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","volume":"5","author":"C Cremolini","year":"2019","unstructured":"Cremolini, C. et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 5, 343 (2019).","journal-title":"JAMA Oncol."},{"key":"965_CR149","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1200\/JCO.2019.37.4_suppl.585","volume":"37","author":"Y Ohhara","year":"2019","unstructured":"Ohhara, Y. et al. Liquid biopsy for optimizing the rechallenge of cetuximab in metastatic colorectal cancer: additional study of E-rechallenge trial. J. Clin. Oncol. 37, 585\u2013585 (2019).","journal-title":"J. Clin. Oncol."},{"key":"965_CR150","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.clcc.2021.07.001","volume":"20","author":"R Moretto","year":"2021","unstructured":"Moretto, R. et al. Rationale and study design of the PARERE trial: randomized phase II study of panitumumab re-treatment followed by regorafenib versus the reverse sequence in RAS and BRAF wild-type chemo-refractory metastatic colorectal cancer patients. Clin. Colorectal Cancer 20, 314\u2013317 (2021).","journal-title":"Clin. Colorectal Cancer"},{"key":"965_CR151","doi-asserted-by":"publisher","first-page":"1307545","DOI":"10.3389\/fonc.2023.1307545","volume":"13","author":"MM Germani","year":"2024","unstructured":"Germani, M. M. et al. Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial. Front. Oncol. 13, 1307545 (2024).","journal-title":"Front. Oncol."},{"key":"965_CR152","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","volume":"7","author":"E Martinelli","year":"2021","unstructured":"Martinelli, E. et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 7, 1529\u20131535 (2021).","journal-title":"JAMA Oncol."},{"key":"965_CR153","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1001\/jamaoncol.2023.0655","volume":"9","author":"S Napolitano","year":"2023","unstructured":"Napolitano, S. et al. Panitumumab plus trifluridine-tipiracil as anti-epidermal growth factor receptor rechallenge therapy for refractory RAS wild-type metastatic colorectal cancer. JAMA Oncol. 9, 966\u2013970 (2023).","journal-title":"JAMA Oncol."},{"key":"965_CR154","doi-asserted-by":"publisher","first-page":"S433","DOI":"10.1016\/j.annonc.2024.08.580","volume":"35","author":"CS Vivas","year":"2024","unstructured":"Vivas, C. S. et al. 511MO \u2014 Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: the randomized phase II CITRIC trial. Ann. Oncol. 35, S433\u2013S434 (2024).","journal-title":"Ann. Oncol."},{"key":"965_CR155","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","volume":"28","author":"A Sartore-Bianchi","year":"2022","unstructured":"Sartore-Bianchi, A. et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat. Med. 28, 1612\u20131618 (2022).","journal-title":"Nat. Med."},{"key":"965_CR156","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele, M. F. et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.Ann. Oncol. 35, 588\u2013606 (2024).","journal-title":"Ann. Oncol."},{"key":"965_CR157","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med. 383, 2207\u20132218 (2020).","journal-title":"N. Engl. J. Med."},{"key":"965_CR158","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ejca.2023.02.016","volume":"186","author":"DT Le","year":"2023","unstructured":"Le, D. T. et al. Pembrolizumab for previously treated, microsatellite instability-high\/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. Eur. J. Cancer 186, 185\u2013195 (2023).","journal-title":"Eur. J. Cancer"},{"key":"965_CR159","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.dld.2020.11.031","volume":"53","author":"J Ta\u00efeb","year":"2021","unstructured":"Ta\u00efeb, J. et al. Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. Dig. Liver Dis. 53, 318\u2013323 (2021).","journal-title":"Dig. Liver Dis."},{"key":"965_CR160","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.annonc.2022.06.008","volume":"33","author":"T Andr\u00e9","year":"2022","unstructured":"Andr\u00e9, T. et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann. Oncol. 33, 1052\u20131060 (2022).","journal-title":"Ann. Oncol."},{"key":"965_CR161","doi-asserted-by":"publisher","first-page":"S174","DOI":"10.1016\/j.annonc.2023.04.501","volume":"34","author":"J Tabernero","year":"2023","unstructured":"Tabernero, J. et al. SO-29 clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis. Ann. Oncol. 34, S174 (2023).","journal-title":"Ann. Oncol."},{"key":"965_CR162","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jama.2022.11238","volume":"328","author":"KP Weinfurt","year":"2022","unstructured":"Weinfurt, K. P. & Reeve, B. B. Patient-reported outcome measures in clinical research. JAMA 328, 472\u2013473 (2022).","journal-title":"JAMA"},{"key":"965_CR163","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","volume":"33","author":"MD Maio","year":"2022","unstructured":"Maio, M. D. et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline. Ann. Oncol. 33, 878\u2013892 (2022).","journal-title":"Ann. Oncol."},{"key":"965_CR164","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.19.03296","volume":"38","author":"S Fukuoka","year":"2020","unstructured":"Fukuoka, S. et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J. Clin. Oncol. 38, 2053\u20132061 (2020).","journal-title":"J. Clin. Oncol."},{"key":"965_CR165","doi-asserted-by":"publisher","first-page":"101917","DOI":"10.1016\/j.eclinm.2023.101917","volume":"58","author":"M Fakih","year":"2023","unstructured":"Fakih, M. et al. Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. EClinicalMedicine 58, 101917 (2023).","journal-title":"EClinicalMedicine"},{"key":"965_CR166","doi-asserted-by":"publisher","unstructured":"Barzi, A. et al. Phase I\/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC). J. Clin. Oncol. 40, https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.015 (2022).","DOI":"10.1200\/JCO.2022.40.4_suppl.015"},{"key":"965_CR167","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/1078-0432.CCR-20-3416","volume":"27","author":"S Cousin","year":"2021","unstructured":"Cousin, S. et al. Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, phase II trial. Clin. Cancer Res. 27, 2139\u20132147 (2021).","journal-title":"Clin. Cancer Res."},{"key":"965_CR168","doi-asserted-by":"publisher","unstructured":"Chung, H. C. et al. LEAP-005: a phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors-results from the gastric cancer cohort. J. Clin. Oncol. 39, https:\/\/doi.org\/10.1200\/JCO.2021.39.3_suppl.230 (2021).","DOI":"10.1200\/JCO.2021.39.3_suppl.230"},{"key":"965_CR169","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.23.02736","volume":"42","author":"A Kawazoe","year":"2024","unstructured":"Kawazoe, A. et al. Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III LEAP-017 study. J. Clin. Oncol. 42, 2918\u20132927 (2024).","journal-title":"J. Clin. Oncol."},{"key":"965_CR170","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","volume":"30","author":"AJ Bullock","year":"2024","unstructured":"Bullock, A. J. et al. Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nat. Med. 30, 2558\u20132567 (2024).","journal-title":"Nat. Med."},{"key":"965_CR171","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1200\/JCO.2024.42.3_suppl.135","volume":"42","author":"PE Oberstein","year":"2024","unstructured":"Oberstein, P. E. et al. Amivantamab monotherapy in relapsed\/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b\/2 study. J. Clin. Oncol. 42, 135 (2024).","journal-title":"J. Clin. Oncol."},{"key":"965_CR172","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2024.42.16_suppl.3008","volume":"42","author":"J Zhao","year":"2024","unstructured":"Zhao, J. et al. Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors. J. Clin. Oncol. 42, 3008 (2024).","journal-title":"J. Clin. Oncol."},{"key":"965_CR173","doi-asserted-by":"publisher","first-page":"S410","DOI":"10.1016\/j.annonc.2023.09.1741","volume":"34","author":"R-H Xu","year":"2023","unstructured":"Xu, R.-H. et al. 550O Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): a phase II study. Ann. Oncol. 34, S410\u2013S411 (2023).","journal-title":"Ann. Oncol."},{"key":"965_CR174","doi-asserted-by":"publisher","first-page":"CT028","DOI":"10.1158\/1538-7445.AM2023-CT028","volume":"83","author":"YR Murciano-Goroff","year":"2023","unstructured":"Murciano-Goroff, Y. R. et al. Abstract CT028: a first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors. Cancer Res. 83, CT028 (2023).","journal-title":"Cancer Res."},{"key":"965_CR175","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1158\/1538-7445.AM2023-526","volume":"83","author":"L Jiang","year":"2023","unstructured":"Jiang, L. et al. Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers. Cancer Res. 83, 526 (2023).","journal-title":"Cancer Res."},{"key":"965_CR176","unstructured":"National Library of Medicine. Study of RMC-6236 in patients with advanced solid tumors harboring specific mutations in RAS. ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT05379985 (2024)."},{"key":"965_CR177","unstructured":"NCI. Study of MRTX1133 in patients with advanced solid tumors harboring a KRAS G12D mutation. cancer.gov, https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2023-02950."},{"key":"965_CR178","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.21873\/anticanres.16629","volume":"43","author":"M Kataoka","year":"2023","unstructured":"Kataoka, M. et al. Cetuximab enhances the efficacy of MRTX1133, a novel KRASG12D inhibitor, in colorectal cancer treatment. Anticancer. Res. 43, 4341\u20134348 (2023).","journal-title":"Anticancer. Res."},{"key":"965_CR179","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/2159-8290.CD-21-1331","volume":"12","author":"MH Hofmann","year":"2022","unstructured":"Hofmann, M. H. et al. Expanding the reach of precision oncology by drugging all KRAS mutants. Cancer Discov. 12, 924\u2013937 (2022).","journal-title":"Cancer Discov."},{"key":"965_CR180","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350\u20131356 (2015).","journal-title":"Nat. Med."},{"key":"965_CR181","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41591-022-02181-8","volume":"29","author":"J Tian","year":"2023","unstructured":"Tian, J. et al. Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nat. Med. 29, 458\u2013466 (2023).","journal-title":"Nat. Med."},{"key":"965_CR182","doi-asserted-by":"publisher","first-page":"TPS234","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS234","volume":"42","author":"VK Morris","year":"2024","unstructured":"Morris, V. K. et al. SWOG S2107: randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and\/or unresectable colorectal cancer. J. Clin. Oncol. 42, TPS234 (2024).","journal-title":"J. Clin. Oncol."},{"key":"965_CR183","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1126\/science.aav4474","volume":"366","author":"M Russo","year":"2019","unstructured":"Russo, M. et al. Adaptive mutability of colorectal cancers in response to targeted therapies. Science 366, 1473\u20131480 (2019).","journal-title":"Science"},{"key":"965_CR184","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.2022.40.4_suppl.012","volume":"40","author":"VK Morris","year":"2022","unstructured":"Morris, V. K. et al. Phase I\/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. J. Clin. Oncol. 40, 12 (2022).","journal-title":"J. Clin. Oncol."},{"key":"965_CR185","doi-asserted-by":"publisher","first-page":"TPS265","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS265","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris, V. K. et al. Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and\/or unresectable colorectal cancer: SWOG S2107. J. Clin. Oncol. 41, TPS265 (2023).","journal-title":"J. Clin. Oncol."},{"key":"965_CR186","doi-asserted-by":"publisher","first-page":"S734","DOI":"10.1016\/j.annonc.2022.07.575","volume":"33","author":"D Paez","year":"2022","unstructured":"Paez, D. et al. 437TiP Trial in progress: a phase III global study of sotorasib, a specific KRAS G12C inhibitor, in combination with panitumumab versus investigator\u2019s choice in chemorefractory metastatic colorectal cancer (CodeBreaK 300). Ann. Oncol. 33, S734 (2022).","journal-title":"Ann. Oncol."},{"key":"965_CR187","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","volume":"20","author":"F Meric-Bernstam","year":"2019","unstructured":"Meric-Bernstam, F. et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 20, 518\u2013530 (2019).","journal-title":"Lancet Oncol."},{"key":"965_CR188","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000911","volume":"5","author":"A Sartore-Bianchi","year":"2020","unstructured":"Sartore-Bianchi, A. et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open 5, e000911 (2020).","journal-title":"ESMO Open"},{"key":"965_CR189","doi-asserted-by":"publisher","first-page":"v199","DOI":"10.1093\/annonc\/mdz246.004","volume":"30","author":"Y Nakamura","year":"2019","unstructured":"Nakamura, Y. et al. TRIUMPH: primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): a GOZILA sub-study. Ann. Oncol. 30, v199\u2013v200 (2019).","journal-title":"Ann. Oncol."},{"key":"965_CR190","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00306","volume":"6","author":"R Gupta","year":"2022","unstructured":"Gupta, R. et al. Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: results from the TAPUR study. JCO Precis. Oncol. 6, e2200306 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"965_CR191","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.clcc.2022.07.003","volume":"21","author":"J Chang","year":"2022","unstructured":"Chang, J. et al. Dual HER2 targeted therapy with pyrotinib and trastuzumab in refractory HER2 positive metastatic colorectal cancer: a result from HER2-FUSCC-G study. Clin. Colorectal Cancer 21, 347\u2013353 (2022).","journal-title":"Clin. Colorectal Cancer"},{"key":"965_CR192","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/annonc\/mdr623","volume":"23","author":"D Santini","year":"2012","unstructured":"Santini, D. et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann. Oncol. 23, 2313\u20132318 (2012).","journal-title":"Ann. Oncol."},{"key":"965_CR193","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/s41416-020-01042-w","volume":"123","author":"T Masuishi","year":"2020","unstructured":"Masuishi, T. et al. Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08. Br. J. Cancer 123, 1490\u20131495 (2020).","journal-title":"Br. J. Cancer"},{"key":"965_CR194","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11523-021-00845-y","volume":"16","author":"A Tsuji","year":"2021","unstructured":"Tsuji, A. et al. Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who obtained clinical benefit from first-line panitumumab-based chemotherapy: JACCRO CC-09. Target. Oncol. 16, 753\u2013760 (2021).","journal-title":"Target. Oncol."},{"key":"965_CR195","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.2022.40.16_suppl.3518","volume":"40","author":"Y Kagawa","year":"2022","unstructured":"Kagawa, Y. et al. Plasma RAS dynamics and anti-EGFR rechallenge efficacy in patients with RAS\/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials. J. Clin. Oncol. 40, 3518 (2022).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00965-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00965-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00965-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T14:03:06Z","timestamp":1734530586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00965-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":195,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["965"],"URL":"https:\/\/doi.org\/10.1038\/s41571-024-00965-0","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"25 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.C. has acted as an adviser and\/or consultant of AstraZeneca, Lilly, Merck, MSD, Nordic Pharma, Roche, Pierre Fabre, Takeda and Tempus; declares speaker\u2019s fees from Amgen, Bayer, MSD, Merck Serono, Pierre Fabre, Servier and Takeda; and has received research grants from Amgen, Merck, Pierre Fabre, Roche, Seagen (Pfizer), Servier, Tempus. C.A. has acted as a consultant and\/or adviser of Takeda and has received speaker\u2019s fees from Merck. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}